Home / Recalls / Contract Pharmaceuticals Limited Canada / D-1139-2023

D-1139-2023 Class III Terminated

Recalled by Contract Pharmaceuticals Limited Canada — Mississauga, N/A

FDA drug recall D-1139-2023 was initiated by Contract Pharmaceuticals Limited Canada on Aug 23, 2023 and is designated Class III. Reason for recall: Defective Container: slow leakage under the cap The recall status is terminated (terminated Aug 6, 2025). Affected quantity: 11,350 bottles.

Recall details

Product Type: Drugs
Report Date: Sep 6, 2023
Initiation Date: Aug 23, 2023
Termination Date: Aug 6, 2025
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 11,350 bottles

Product description

Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottle, Rx only, Manufactured by: Contract Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, Manufactured for: Glasshouse Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, NDC# 71428-003-60

Reason for recall

Defective Container: slow leakage under the cap

Distribution pattern

Nationwide in the USA.

Code information

Lot # 118920, exp. January 2024.

Source

Dataset: openFDA drug recall enforcement reports
FDA record: This recall in openFDA (JSON)
Enforcement Report: Search FDA's Enforcement Report for D-1139-2023
openFDA file date: Nov 10, 2026
Loaded by RegDataLab: Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.